Abstract
During repair of connective tissue, resting fibroblasts become ‘activated’; that is, they migrate into the wound where they synthesize and remodel new extracellular matrix. The differentiated fibroblast responsible for this action is termed the myofibroblast, which expresses the highly contractile protein α—smooth muscle actin (α—SMA) and is responsible for the synthesis and remodeling of extracellular matrix (ECM). Persistence of the myofibroblast is a key characteristic of fibrotic diseases including scleroderma. Proteins such as transforming growth factorβ (TGFβ), endothelin-1 (ET- 1), connective tissue growth factor (CCN2/CTGF) and platelet derived growth factor (PDGF) are believed to contribute to myofibroblast differentiation and persistence. Moreover, it is now known that elevated adhesive and contractile signaling is a key feature of fibrotic fibroblasts. This review summarizes recent findings aimed at developing new, rationally-designed therapies for the fibrosis in scleroderma.
Current Enzyme Inhibition
Title: Sticking it to Scleroderma: Potential Therapies Blocking Elevated Adhesive and Contractile Signaling
Volume: 6 Issue: 2
Author(s): Andrew Leask
Affiliation:
Keywords: PDGF, TGFβ, endothelin, rac, PPARγ, PKCε
Abstract: During repair of connective tissue, resting fibroblasts become ‘activated’; that is, they migrate into the wound where they synthesize and remodel new extracellular matrix. The differentiated fibroblast responsible for this action is termed the myofibroblast, which expresses the highly contractile protein α—smooth muscle actin (α—SMA) and is responsible for the synthesis and remodeling of extracellular matrix (ECM). Persistence of the myofibroblast is a key characteristic of fibrotic diseases including scleroderma. Proteins such as transforming growth factorβ (TGFβ), endothelin-1 (ET- 1), connective tissue growth factor (CCN2/CTGF) and platelet derived growth factor (PDGF) are believed to contribute to myofibroblast differentiation and persistence. Moreover, it is now known that elevated adhesive and contractile signaling is a key feature of fibrotic fibroblasts. This review summarizes recent findings aimed at developing new, rationally-designed therapies for the fibrosis in scleroderma.
Export Options
About this article
Cite this article as:
Leask Andrew, Sticking it to Scleroderma: Potential Therapies Blocking Elevated Adhesive and Contractile Signaling, Current Enzyme Inhibition 2010; 6 (2) . https://dx.doi.org/10.2174/157340810791232999
DOI https://dx.doi.org/10.2174/157340810791232999 |
Print ISSN 1573-4080 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6662 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pharmacologically Targeting the Primary Defect and Downstream Pathology in Duchenne Muscular Dystrophy
Current Gene Therapy Cyclosporine A: Chemistry and Toxicity – A Review
Current Medicinal Chemistry Capillaroscopy in Routine Diagnostics: Potentials and Limitations
Current Rheumatology Reviews The Role of Pro-fibrotic Myofibroblasts in Systemic Sclerosis: From Origin to Therapeutic Targeting
Current Molecular Medicine Hydroxyproline: A Potential Biochemical Marker and Its Role in the Pathogenesis of Different Diseases
Current Protein & Peptide Science Macrophage Migration Inhibitory Factor - A Favorable Marker in Inflammatory Diseases?
Current Medicinal Chemistry Alginates in Pharmaceutics and Biomedicine: Is the Future so Bright?
Current Pharmaceutical Design Patent Annotations
Recent Patents on Anti-Infective Drug Discovery Enteral and Parenteral Nutrition Therapy for Crohns Disease
Current Pharmaceutical Design Clinical Aspects and Therapeutic Perspectives of Relaxin
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Gauzoma in A Scleroderma Patient Following Open Heart Surgery: A Case Report
Current Rheumatology Reviews Inhibitory Smad7: Emerging Roles in Health and Disease
Current Molecular Pharmacology Pathogenesis and Therapeutics of Interstitial Lung Disease in Systemic Sclerosis
Current Rheumatology Reviews Synthetic Peptides for the Immunodiagnosis of Human Diseases
Current Medicinal Chemistry Editorial: Nailfold Capillaroscopy in Rheumatology
Current Rheumatology Reviews Juvenile Scleroderma-What has Changed in the Meantime?
Current Rheumatology Reviews Microvascular Diseases: Is A New Era Coming?
Cardiovascular & Hematological Agents in Medicinal Chemistry Recent Advances in the Treatment of Interstitial Lung Disease in Patients with Polymyositis/Dermatomyositis
Endocrine, Metabolic & Immune Disorders - Drug Targets Mixed Connective Tissue Disease, a Roundabout to Rheumatic Diseases?
Current Rheumatology Reviews Pharmacologic Ovarian Preservation in Young Women Undergoing Chemotherapy
Current Medicinal Chemistry